Clascoterone 1% cream in acne vulgaris: a profile of its use

Funding The preparation of this review was not supported by any external funding.

Authorship and conflicts of interest E.S. Kim and Susan J. Keam are contracted/salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable

Additional information about this Adis Drug Review can be found here.

AbstractClascoterone 1% cream (Winlevi^®) is an androgen receptor inhibitor approved for the topical treatment of acne vulgaris in patients aged ≥12 years in the USA. It is believed to compete with androgens (specifically Dihydrotestosterone) in binding to androgen receptors, thereby inhibiting downstream signaling of acnegenic pathways. In clinical trials, application of clascoterone 1% cream twice daily for 12 weeks was effective and generally well tolerated in acne vulgaris patients, with a tolerability profile similar to that of the vehicle.